Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 ARROW study

被引：0
|
作者：
Mateos, Maria-Victoria [1 ]
Ludwig, Heinz [2 ]
Kumar, Shaji [3 ]
Rosenbaum, Cara [4 ]
Huang, Mei [5 ]
Goldrick, Amanda [5 ]
Blaedel, Julie [5 ]
Dimopoulos, Meletios A. [6 ]
机构：
[1] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[2] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria
[3] Mayo Clin, Rochester, MN USA
[4] Weill Cornell Med, New York, NY USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
carfilzomib; frailty; Relapsed Refractory MM;
D O I：
10.1016/j.clml.2019.09.047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-046
引用
收藏
页码：E31 / E32
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
    Reece, Donna E.
    Hegenbart, Ute
    Sanchorawala, Vaishali
    Merlini, Giampaolo
    Palladini, Giovanni
    Blade, Joan
    Fermand, Jean-Paul
    Hassoun, Hani
    Heffner, Leonard
    Vescio, Robert A.
    Liu, Kevin
    Enny, Christopher
    Esseltine, Dixie-Lee
    van de Velde, Helgi
    Cakana, Andrew
    Comenzo, Raymond L.
    BLOOD, 2011, 118 (04) : 865 - 873
  • [22] Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludek
    Weisel, Katja
    Coriu, Daniel
    Obreja, Michaela
    Goldrick, Amanda
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S332 - S333
  • [23] A phase 1b study of once-weekly carfilzomib combined with lenalido-mide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM)
    Alsina, Melissa
    Landgren, C. Ola
    Raje, Noopur
    Niesvizky, Ruben
    Bensinger, William I.
    Berdeja, Jesus
    Kovacsovics, Tibor
    Vesole, David
    Fang, Belle
    Kimball, Amy
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E52 - E52
  • [24] Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure
    Berdeja, Jesus G.
    Rifkin, Robert M.
    Lyons, Roger
    Yang, Hui
    Zahlten-Kuemeli, Anita
    Aggarwal, Sanjay K.
    Iskander, Karim
    Berenson, James
    BLOOD, 2016, 128 (22)
  • [25] A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    Alsina, Melissa
    Landgren, Ola
    Raje, Noopur
    Niesvizky, Ruben
    Bensinger, William I.
    Berdeja, Jesus G.
    Kovacsovics, Tibor
    Vesole, David H.
    Fang, Belle
    Kimball, Amy S.
    Siegel, David S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (02) : 226 - 233
  • [26] Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
    Bringhen, Sara
    Mina, Roberto
    Petrucci, Maria Teresa
    Gaidano, Gianluca
    Ballanti, Stelvio
    Musto, Pellegrino
    Offidani, Massimo
    Spada, Stefano
    Benevolo, Giulia
    Ponticelli, Elena
    Galieni, Piero
    Cavo, Michele
    Di Toritto, Tommaso Caravita
    Di Raimondo, Francesco
    Montefusco, Vittorio
    Palumbo, Antonio
    Boccadoro, Mario
    Larocca, Alessandra
    HAEMATOLOGICA, 2019, 104 (08) : 1640 - 1647
  • [27] Once-weekly (70 mg/m2) versus twice weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
    Moreau, Philippe
    Stewart, A. Keith
    Dimopoulos, Meletios A.
    Siegel, David Samuel DiCapua
    Facon, Thierry
    Berenson, James R.
    Raje, Noopur S.
    Berdeja, Jesus G.
    Orlowski, Robert Z.
    Yang, Hui
    Ma, Haijun
    Karina Klippel, Zandra
    Zahlten-Kumeli, Anita
    Mezzi, Khalid
    Iskander, Karim
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Zhou, Yan
    Zhu, Jiankun
    Wu, Haiya
    Deng, Yuying
    Ji, Qiuhe
    DIABETES THERAPY, 2021, 12 (10) : 2677 - 2690
  • [29] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Yan Zhou
    Jiankun Zhu
    Haiya Wu
    Yuying Deng
    Qiuhe Ji
    Diabetes Therapy, 2021, 12 : 2677 - 2690
  • [30] Efficacy and Safety of Once-Weekly versus Twice-Weekly Bortezomib in Patients with Hematologic Malignancies: A Meta-analysis with Trial Sequential Analysis
    Hu, Bin
    Zhou, Quan
    Hu, Yang-yang
    Zhuang, Lan
    Yi, Li-ping
    Cao, Jin-xia
    Li, Tian-qi
    Wang, Jun
    PHARMACOTHERAPY, 2019, 39 (06): : 697 - 708
12345